Background To date, there has been no reliable in vitro test to diagnose aspirin-exacerbated respiratory disease (AERD). Objective To investigate potential diagnostic biomarkers for AERD using metabolomic analysis. Methods An untargeted profile of serum from asthmatics in the first cohort (group 1) comprising 45 AERD, 44 patients with aspirin-tolerant asthma (ATA), and 28 normal controls was developed using the ultra-high-performance liquid chromatography (UHPLC)/QToF MS system. Metabolites that discriminate AERD from ATA were quantified in both serum and urine, which were collected before (baseline) and after the lysine-aspirin bronchoprovocation test (Lys-ASA BPT). The serum metabolites were validated in the second cohort (group 2) comprising 50 patients with AERD and 50 patients with ATA. Results A clear discrimination of metabolomes was found between patients with AERD and ATA. In group 1, serum levels of LTE 4 and LTE 4 /PGF 2 a ratio before and after the Lys-ASA BPT were significantly higher in patients with AERD than in patients with ATA (P < 0.05 for each), and urine baseline levels of these two metabolites were significantly higher in patients with AERD. Significant differences of serum metabolite levels between patients with AERD and ATA were replicated in group 2 (P < 0.05 for each). Moreover, serum baseline levels of LTE 4 and LTE 4 /PGF 2 a ratio discriminated AERD from ATA with 70.5%/71.6% sensitivity and 41.5%/62.8% specificity, respectively (AUC = 0.649 and 0.732, respectively P < 0.001 for each). Urine baseline LTE 4 levels were significantly correlated with the fall in FEV 1 % after the Lys-ASA BPT in patients with AERD (P = 0.008, r = 0.463). Conclusions and Clinical Relevance Serum metabolite level of LTE 4 and LTE 4 /PGF 2 a ratio was identified as potential in vitro diagnostic biomarkers for AERD using the UHPLC/QToF MS system, which were closely associated with major pathogenetic mechanisms underlying AERD.
Introduction
Aspirin-exacerbated respiratory disease (AERD) is characterized by the presence of asthma, chronic rhinosinusitis with nasal polyps, and hypersensitivity to aspirin/nonsteroidal anti-inflammatory drugs (NSAIDs).
Previous studies demonstrated that patients with AERD experience more severe bronchial obstruction, frequent emergency department visits/hospitalizations, and corticosteroid bursts compared to those with aspirin-tolerant asthma (ATA) [1] [2] [3] . It is clinically important to diagnose AERD in order for the avoidance of aspirin/ NSAIDs and alternative treatment of patients, including biologics and aspirin desensitization.
*Both authors contributed equally to this work.
A history of asthma exacerbation after exposure to aspirin/NSAIDs is strongly suggestive of AERD; however, there is a wide discrepancy between history and symptom upon exposure to aspirin/NSAIDs [3] . To confirm the diagnosis of AERD, oral/nasal aspirin challenge and the lysine-aspirin bronchial provocation test (Lys-ASA BPT) are known to be as the most reliable methods. However, adverse reactions caused by provocation tests, ethical issues, and/or contraindications, including low lung function, make investigators develop appropriate in vitro diagnostic tests [4] . Dysregulation of arachidonic acid metabolism has been demonstrated to be notably involved in pathogenesis of AERD. Decreased metabolites of cyclooxygenase (COX) pathway (e.g. PGs and TXB 2 ) and increased metabolites of lipoxygenase (LOX) pathway (e.g. cysLTs) in patients with AERD are key features underlying pathogenesis. A few in vitro tests which evaluate the metabolites involved in arachidonic acid metabolism have been proposed to diagnose AERD. Aspirin-sensitive patients identification test measures cysteinyl leucotrienes (cysLTs), and 15-hydroxyeicosatetraenoic acid generation assay evaluates the release of 15-hydroxyeicosatetraenoic acid from peripheral blood leucocytes after NSAID stimulation [2, 4] . However, none of these in vitro tests are recommended for a diagnosis of AERD because of low sensitivity/specificity and lack of clinical utility.
Metabolomics is a high-throughput method for assessing the pathophysiological state and for identifying novel biomarkers to understand molecular mechanisms of the disease [5] . Main metabolic fingerprinting approaches are nuclear magnetic resonance (NMR) and mass spectrometry (MS) [6] . While NMR provides highly reproducible results, it is relatively insensitive. MS is the most sensitive approach that can potentially measure compounds in the picomolar range [7] . The high sensitivity of MS makes it an essential approach to assessment of metabolites in body fluids, such as urine, plasma, serum, exhaled breath condensate (EBC), and bronchoalveolar lavage fluid [6, 8] .
Several studies have applied metabolomics to asthmatics and identified specific metabolic profiles, which distinguish asthmatics from healthy controls [9, 10] , stable asthmatics from exacerbated asthmatics [11] , and mild asthmatics from severe asthmatics [12] . However, there have been few reports employing metabolomics to discover diagnostic biomarkers for AERD.
We hypothesized that the metabolic profile of AERD is distinct from that of ATA and applied an integrated approach combined with the ultra-high-performance liquid chromatography (UHPLC) MS system to analyse serum and urine samples from patients with AERD compared to those from patients with ATA and healthy controls, which was validated in the second cohort of patients with AERD/ATA. The effects of aspirin challenge on metabolites were compared between patients with AERD and ATA. In addition, we further identified correlations between each metabolite and clinical parameters to investigate the utility of metabolomics not only in the diagnosis of AERD, but also in assessing severity/degree of airway inflammation.
Methods

Subjects
The study population consisted of the first cohort, group 1 (45 patients with AERD and 44 patients with ATA), the second cohort, group 2 (50 patients with AERD and 50 patients with ATA), and 28 normal healthy controls which were recruited from Ajou University Hospital in Korea. The two groups of patient cohort were completely different. AERD was diagnosed using a typical clinical history (recurrent exacerbation of upper or lower respiratory reactions after ingestion of aspirin/NSAIDs) and/or a positive response to the Lys-ASA BPT. Subjects who showed negative results to the Lys-ASA BPT or denied any changes in upper or lower respiratory tract symptoms after ingestion of aspirin/NSAIDs were defined as ATA. All antiasthmatic drugs, including leucotriene modifiers, were stopped for at least 3 days before the Lys-ASA BPT. The Lys-ASA BPT was performed with increasing doses of Lys-ASA solution up to 300 mg/mL using methods previously described [13] . The result of the Lys-ASA BPT was defined as positive when FEV 1 % was decreased by more than 20% after challenge. Severe asthma was diagnosed according to the definition of the American Thoracic Society workshop [14] . Each study participant provided informed consent. The protocol was approved by the Institutional Review Board of Ajou University Hospital (AJIRB-GEN-SMP-13-108).
Collection of the samples
Peripheral venous blood and urine samples were collected before the Lys-ASA BPT (between 8:00 and 10:00 in the morning) in group 1 patients. The second sampling was performed at the time of development of lower respiratory symptoms after exposure to Lys-ASA in patients with AERD and 4 h after the last dose of Lys-ASA in patients with ATA. From group 2 patients, serum samples were collected once when the disease was stable with regular maintenance medication including inhaled corticosteroid, long-acting beta-agonist, leucotriene modifiers.
Untargeted metabolite profiling
Sample preparation. Aliquots of the frozen serum and urine were thawed. Serum samples were extracted with 80% methanol, and urine samples were diluted five times with water. All the samples were mixed for 10 min and centrifuged at 18 341 g for 20 min at 4°C.
Chromatography and TOF-MS conditions. Five microlitres of each sample were injected into the column held at 40°C and eluted with 0.1% formic acid and 20 mM ammonium formate in water (solvent A), and 0.1% formic acid in methanol (solvent B) over 21 min. Each metabolite was eluted at a constant flow rate of 0.4 mL/min using the following gradient: 2-98% B from 0.1 to 13 min and 98% B held constant for 2 min followed by a return to 2% B from 15.1 to 17 min. Chromatographic separation of metabolites in serum and urine was performed with a ACQUITY UPLC BEH C18, 2.1 9 50-mm, 1.7-lm (Waters, Milford, MA, USA) analytical column using the Agilent 1290 Infinity II UHPLC system (Agilent Technologies, Santa Clara, CA, USA).
Each eluent was introduced into an Agilent 6530 quadrupole time-of-flight (Q-TOF) mass spectrometer. The device settings have been described in a previous study in detail [15] . The overall quality of the analysis procedure was monitored using repetition of a pooled serum or urine sample (data not shown).
Data processing and multivariate data analysis. All raw data files were transformed to the compound exchange file format using MASSHUNTER DA REPROCESSOR software B.04.00 (Agilent Technologies). Mass Profiler Professional (MPP) software B.12.01 (Agilent Technologies) was used for aligning and converting each metabolite feature (m/z 9 intensity 9 time) into a matrix of detected peaks vs. compound identification. Data were normalized to the median of the baseline and log 2-transformed, baseline corrected, and full description first retention time (RT) aligned.
The intensity of each compound was normalized with respect to the total ion count to generate a data matrix that consisted of the normalized peak area, RT, and m/z value. The multivariate data matrix was analysed by an MPP software package, which was used to perform principal components analysis (PCA) and partial least squares discriminant analysis (PLS-DA), and makes volcano plots for both positive and negative electrospray ionization datasets to select (filtered by following threshold; fold change ≤ 0.66 or fold change ≥ 1.5, and P < 0.05) key metabolites discriminating different metabolome between AERD and ATA groups.
Biomarker identification. The resulting compounds were identified using the human metabolome database, METLIN, and the MS/MS fragment pattern with authentic analytical standards. The identities of the specific metabolites were confirmed by comparing chromatographic RTs, and their mass spectra to those obtained using commercially available reference standards.
Quantification of metabolites
MassHunter Quantitative Analysis B.07.00 (Agilent Technologies) was used to quantify LTE 4 , prostaglandin F 2 a (PGF 2 a), 11-dehydro thromboxane B 2 (TXB 2 ), and eoxin C 4 in serum and urine samples. The following deuterated internal standards were used as follows: LTE 4 -d5 for LTE 4 , 8-iso PGF 2 a-d4 for PGF 2 a, 11-dehydro TXB 2 -d4 for 11-dehydro TXB 2 , and LTC 4 -d5 for eoxin C 4 (Cayman Chemical Company, Ann Arbor, MI, USA). In urine samples, creatinine was also quantified to normalize to the actual concentrations of each biomarker and 1,3-dimethyl-2-imidazolidinone (SigmaAldrich, St. Louis, MO, USA) and used as the internal standard for creatinine. The concentration of each biomarker was determined from calibration curves using linear regression analysis. Correlation coefficients were > 0.99 for all biomarkers. All chemicals were of HPLC grade.
Statistical analysis
Student's t-test and the chi-square test were used to compare continuous and dichotomous variables. The Wilcoxon signed-rank test compared paired continuous variables. Pearson's correlation analysis identified associations among continuous variables. A receiver operating characteristic curve analysis was used to discriminate AERD from ATA. General linear regression analysis was performed to adjust for confounding factors to compare metabolite levels between patients with AERD and ATA.
Results
Baseline clinical characteristics of the study subjects
This study first analysed the first cohort, group 1 subjects, and then the second cohort, group 2 subjects. Table 1 shows the clinical characteristics of groups 1 and 2 subjects. In group 1, there were no significant differences in baseline characteristics between patients with AERD and ATA. The number of severe asthmatics was four in patients with ATA and 10 in patients with AERD (P = 0.089). In group 2, the number of nonatopic patients was significantly higher, and baseline FEV 1 was lower in patients with AERD (P = 0.047, P = 0.014). In group 2, the number of severe asthmatics was three in patients with ATA and eight in patients with AERD (P = 0.110). There were no statistical differences in clinical characteristics between groups 1 and 2 subjects. The mean age of normal controls was 26.19 AE 3.28 years, and there were eight female patients.
Untargeted metabolomic analysis in patients with aspirin-exacerbated respiratory disease and aspirintolerant asthma
We performed untargeted metabolomic analyses through the UHPLC/Q-ToF MS system to identify differences in metabolites between patients with AERD and ATA. PCA presented different signatures of metabolomes between patients with AERD and ATA in positive and negative ion modes with overall accuracies of 79.070% and 73.256%, respectively ( Fig. S1a and d) . We also performed PLS-DA, which is a supervised method informed by intergroup variability, for improving separation between groups ( 2 Y = 0.858, respectively) and resulted in improved overall accuracies of 100% in both ion modes. Among the metabolomes, the key metabolites which showed significant differences between AERD and ATA groups were selected from volcano plots containing filter threshold information(fold change ≤ 0.66 or fold change ≥ 1.5, and P < 0.05) (Fig. S1c and f) . Among nine metabolites selected, six were identifiable based on the database and the MS/MS fragment pattern of pure analytical standards: ureidosuccinicacid, N-acetylvanilalanine, 3-ketosphingosine, PGF 2 a, LTE 4 , and sphingomyelin (d18:0/13:0) (Table S1 ). From the results of untargeted metabolomic analysis, we found that eicosanoid associated with arachidonic acid was related to the phenotype of AERD. Subsequently, we further quantified each metabolite, including LTE 4 , PGF 2 a, 11-dehydro TXB 2 , and eoxin C 4 , and compared between patients with AERD and ATA.
Comparison of serum metabolite levels between normal controls and asthmatic patients (aspirin-exacerbated respiratory disease and aspirin-tolerant asthma) Serum levels of LTE 4 , PGF 2 a, LTE 4 /PGF 2 a ratio, 11-dehydro TXB 2 , and eoxin C 4 in normal controls were 15.12 AE 3.22 pg/mL, 22.31 AE 13.31 pg/mL, 0.69 AE 0.18, 0.27 AE 0.14 ng/mL, and 1.27 AE 0.88 pg/mL, respectively. Serum levels of LTE 4 , PGF 2 a, and 11-dehydro TXB 2 showed no significant differences between normal healthy controls and asthmatic patients, while serum level of eoxin C 4 was significantly higher in asthmatic patients than in normal controls (P = 0.025) after adjusting for age and sex.
Serum levels of LTE 4 , PGF 2 a, 11-dehydro TXB 2 , and eoxin C 4 before and after the Lys-ASA BPT in group 1
In group 1, serum LTE 4 levels before and after Lys-ASA BPT were significantly higher in patients with AERD than those with ATA (P = 0.006 and P < 0.001, respectively). Serum LTE 4 levels did not change after Lys-ASA BPT in patients with AERD and ATA (Fig. 1a) . Serum PGF 2 a levels showed no significant differences between in patients with ATA and AERD. Serum PGF 2 a levels did not change after Lys-ASA BPT (Fig. 1b) . Serum LTE 4 /PGF 2 a ratios before and after Lys-ASA BPT were significantly higher in patients with AERD than those with ATA (P = 0.003 and P < 0.001, respectively). Serum LTE 4 /PGF 2 a ratios of ATA decreased significantly (P = 0.037) while those of AERD did not change after Lys-ASA BPT (Fig. 1c) . Serum TXB 2 levels showed no significant difference between in patients with ATA and AERD. Serum TXB 2 levels increased significantly after Lys-ASA BPT in patients with ATA and AERD (P = 0.009 and P < 0.001, respectively) (Fig. 2a) . Serum baseline eoxin C 4 levels tended to be higher in patients with AERD than in patients with ATA (P = 0.065), but after the Lys-ASA BPT, they were significantly higher in patients with AERD (P = 0.006). Serum eoxin C 4 levels significantly increased after Lys-ASA BPT in AERD (P < 0.001) while no change was observed in patients with ATA (Fig. 2b) .
Urine levels of LTE 4 , PGF 2 a, 11-dehydro TXB 2 , and eoxin C 4 before and after the Lys-ASA BPT in group 1
Urine LTE 4 levels before Lys-ASA BPT were significantly higher in patients with AERD than in patients with ATA (P = 0.033) while those after Lys-ASA BPT showed no difference between AERD and ATA. Urine LTE 4 levels did not change after Lys-ASA BPT in ATA and AERD (Fig. 3a) . Urine PGF 2 a levels before and after Lys-ASA BPT showed no significant difference between in patients with ATA and AERD. Urine PGF 2 a levels did not change after Lys-ASA BPT in AERD and ATA (Fig. 3b) . Urine LTE 4 /PGF 2 a ratios before and after Lys-ASA BPT were significantly higher in patients with AERD than in those with ATA (P = 0.006 and P = 0.032, respectively). Urine LTE 4 /PGF 2 a ratios of ATA increased significantly after Lys-ASA BPT in patients with ATA (P = 0.027) while no change was observed in patients with AERD (Fig. 3c) . Urine TXB 2 levels showed no significant difference between in patients with ATA and AERD. Urine TXB 2 levels increased significantly after Lys-ASA BPT in ATA and AERD (P = 0.026 and P = 0.002, respectively) (Fig. 4a) . Urine eoxin C 4 levels showed no significant difference between in patients with ATA and AERD. Urine eoxin C 4 levels did not change after Lys-ASA BPT in AERD and ATA (Fig. 4b) .
Validation of serum levels of the metabolites in the second cohort (group 2)
In group 2, serum levels of LTE 4 and LTE 4 /PGF 2 a ratios were significantly higher, but serum PGF 2 a levels were lower in patients with AERD than in patients with ATA (P = 0.049, P = 0.001, and P = 0.008, respectively) ( Fig. 5a-c) . In the total group (first plus second cohort), serum baseline eoxin C 4 levels were significantly higher in patients with AERD than in patients with ATA (P = 0.026).The cut-off value of the serum LTE 4 and LTE 4 /PGF 2 a ratio for discriminating AERD from ATA was 11.87 pg/mL, with 70.5% sensitivity and 41.5% specificity (AUC = 0.649, P < 0.001) and 0.66, with 71.6% sensitivity and 62.8% specificity (AUC = 0.732, P < 0.001), respectively. Serum levels of LTE 4 , PGF 2 a, and LTE 4 /PGF 2 a ratio showed significant difference between AERD and ATA after adjusting group, age, and gender in general linear model (P = 0.004, P = 0.003, and P < 0.001, respectively).
Association of each metabolite with clinical parameters
Serum levels of LTE 4 and PGF 2 a showed no associations with clinical parameters in terms of FEV 1 %, methacholine PC 20 value, blood/sputum eosinophil count, severity of asthma (severe vs. nonsevere asthma), and presence of atopy or chronic rhinosinusitis (CRS)/nasal polyp in patients with AERD, while significant correlations were found between serum baseline LTE 4 /PGF 2 a ratio and decreases in FEV 1 % after the Lys-ASA BPT (r = 0.217, P = 0.036). Moreover, urine baseline LTE 4 levels were significantly correlated with decreases in FEV 1 % after the Lys-ASA BPT (r = 0.463, P = 0.008). Serum and urine baseline levels of the metabolites showed no significant differences in asthma severity. Serum baseline eoxin C 4 levels were significantly correlated with LTE 4 levels (r = 0.347, P < 0.001) in patients with AERD, while no correlations were found in patients with ATA.
Discussion
To date, the provocation test with aspirin has been regarded as the gold standard for the diagnosis of AERD. However, considering some limitations in performing the provocation test with aspirin, including ethical issues and unavailability of equipment, it is necessary to develop a reliable in vitro test. Given that the imbalance of the eicosanoid cascade is the most important pathogenetic mechanism underlying AERD, a few in vitro tests regarding arachidonic pathway have been suggested [4] . However, most of these tests are rarely recommended as routine diagnostic tests. This is the first study to perform metabolomic analysis to identify serum diagnostic biomarkers for AERD. In the present study, several metabolites of arachidonic acid pathway discriminated AERD from ATA by untargeted metabolomic analysis; thereafter, we further analysed each metabolite level involved in arachidonic acid pathway using targeted metabolomic analysis and demonstrated that serum baseline levels of LTE 4 and LTE 4 /PGF 2 a ratios can be useful diagnostic biomarkers for AERD. The strength of the present study is that we overcame the main issue of previous metabolomic studies [9] , such as small sample size, medication control status, and validation in a different cohort. We enrolled well-controlled subjects that stopped all asthma medications, including leucotriene modifiers, before sample collection in group 1. A total of 89 patients classified into AERD and ATA were enrolled for untargeted metabolomic analysis. All the results were validated in the second cohort comprising 100 subjects. Serum is easy to collect compare to urine or tissue samples. Therefore, we propose that serum metabolites identified in the present study can be a new alternative and clinically convenient biomarker for the in vitro diagnosis of AERD. Metabolomic analysis has been used to differentiate asthmatic patients from healthy controls or from chronic obstructive pulmonary disease [6, 16] . It is necessary to develop biomarkers that represent specific phenotypes or endotypes of asthma because of its heterogeneity [17] . A previous study demonstrated that specific regions of NMR discriminate the phenotype of neutrophilic asthma [18] . The endotype of high F E NO asthmatics showed a higher level of taurocholate than that of low F E NO asthmatics [19] . A few serum metabolites, including choline and arginine, showed positive correlations with FEV 1 % values [20] . However, most metabolites to date are neither directly related to the pathogenesis of asthma nor easy to measure repeatedly in clinical practice. There have been no studies evaluating whether the untargeted metabolomic approach can differentiate AERD from ATA. The present study provides a new application of serum and urine metabolites to determine the phenotype of AERD compared to ATA and normal controls, which has a potential clinical implication because 4 /PGF 2 a ratios (c), 11-dehydro TXB 2 (d), and eoxin C 4 (e) collected before the Lys-ASA BPT in patients with AERD and ATA in group 2. All serum metabolites in ATA and AERD were measured by ultra-high-performance liquid chromatography (UHPLC)/Q-ToF MS method. Data are shown as mean AE SD. Comparison of metabolites between AERD and ATA was performed by general linear regression analysis adjusted by age and gender. Wilcoxon signed-rank test was used to evaluate the change of metabolite levels after Lys-ASA BPT. Lys-ASA BPT, lysine-aspirin bronchoprovocation test; AERD, aspirin-exacerbated respiratory disease; ATA, aspirin-tolerant asthma.
there has been no useful in vitro diagnostic test for AERD.
The pathogenesis of AERD is derived from dysregulation of arachidonic acid metabolism. Aspirin/NSAIDs inhibit COX enzymes and divert arachidonic acid to the LOX pathway [21] . They lead to increases in cysLTs and reductions in PGs [22] . Abnormalities in eicosanoid biosynthesis have been found in bronchoalveolar lavage, sputum, EBC, saliva, plasma, and urine [23] . Patients with AERD exhibit significantly higher levels of LTE 4 in urine [24] [25] [26] , saliva, and sputum [25] at baseline compared to patients with ATA. Plasma LTE 4 metabolite levels have been reported to be higher in patients with occupational asthma, steroid-resistant asthma, and moderate asthma [27] . In line with these findings, serum and urine baseline metabolite levels of LTE 4 were significantly higher in patients with AERD than in patients with ATA. This is the first study to demonstrate that the serum baseline LTE 4 level examined by the UHPLC/QToF MS system is significantly different between patients with AERD and ATA, even after adjusting for the confounders including baseline FEV 1 % [27] by general linear regression analysis (P = 0.001, F = 10.40; data not shown). Moreover, reciever operating characteristic (ROC) analysis revealed that the serum LTE 4 level can be a useful marker for discriminating AERD with high sensitivity. These findings collectively imply that the serum LTE 4 metaboblite level can be a potential biomarker for determining the phenotype of AERD.
CysLTs are strong inflammatory bronchoconstrictors that involve Th2-type cytokine and mucus production as well as airway smooth muscle and goblet cell hyperplasia [28, 29] . In the present study, urine baseline LTE 4 levels were correlated with decreases in FEV 1 % after the Lys-ASA BPT in line with previous studies [26, 30] . However, baseline LTE 4 levels were not correlated with baseline FEV 1 % or asthma severity, which is inconsistent with results of previous studies [27, 31] . The reason for the discrepancy may be due to the heterogeneity of study subjects.
Compared to the metabolites of the 5-LOX pathway, those of the 15-LOX pathway have been less studied. In the present study, serum baseline levels of eoxin C 4 were higher in asthmatics than in normal controls, which is consistent with a previous study of EBC [32] . A previous study showed that 12/15-LOX (analogue to human 15-LOX) knockout mice had impaired development of allergic airway inflammation induced by Th2 cytokines [33] , suggesting that 12/15-LOX-derived metabolites may play a role in Th2-induced inflammation in asthma. Eoxins are known as 15-LOX analogues of cysLTs, and their biological properties regarding the permeability-increasing activity are similar [28] . It is suggested that eoxin overproduction may be involved in the pathogenesis of AERD [28] ; however, high eoxin levels are not consistently reported in AERD [34, 35] . This is the first study to report that identified serum eoxin C 4 metabolite levels are higher in patients with AERD than in patients with ATA and increased significantly during the Lys-ASA BPT in patients with AERD. Eoxins have been reported to enhance vascular permeability, a hallmark of inflammation, and suggested to be almost as potent as cysLTs [36] . Increased eoxin levels have been shown to be associated with increased bronchial hyperresponsiveness in childhood asthmatics [32] . Taken together, our findings imply that eoxin may play potential proinflammatory roles in upper and lower airway inflammation of AERD, which needs to be further investigated, but can provide a novel therapeutic target for AERD other than leucotriene receptor antagonists.
There is much evidence that metabolites in the COX pathway are downregulated in patients with AERD. The baseline levels of PGE 2 [37, 38] and TXB 2 [34] are significantly lower, whereas those of PGD 2 (a biomarker of mast cell activation) are higher in patients with AERD than in patients with ATA [24, 34] . PGF 2 a levels have been examined in several studies [34, 35, [37] [38] [39] [40] , but significant differences between AERD and ATA have rarely been reported. In a previous study, plasma PGF 2 a levels were lower in patients with AERD, which were increased after incubation in the aspirin in vitro setting, while no changes were noted in patients with ATA [40] . Based on this finding, the serum PGF 2 a test has been suggested to be useful for the diagnosis of AERD when serum PGF 2 a levels are increased after addition of aspirin [4] . Our study demonstrated that serum baseline PGF 2 a metabolite levels were significantly lower in patients with AERD in the total group (P = 0.002, data not shown), indicating the downregulation of the COX pathway in patients with AERD. To identify the LTs/PGs imbalance in patients with AERD, we further analysed the ratio of LTE 4 to PGF 2 a and showed that serum and urine baseline levels were significantly higher in patients with AERD than in patients with ATA, which were similar after the Lys-ASA BPT. ROC analysis revealed that LTE 4 /PGF 2 a ratios in serum and urine discriminated AERD from ATA better than LTE 4 levels. These findings lead us to speculate that the LTE 4 /PGF 2 a metabolite ratio can be a better potential serum/urine biomarker for determining the phenotype of AERD.
Previous studies [24, 25, 35, 37, 39, 40] showed changes in LT levels in urine, EBC, or saliva after oral or inhaled aspirin challenge tests. Some types of samples, such as EBC [35, 40] or saliva [25] , are inappropriate for monitoring changes in metabolites after provocation. In the present study, however, levels of LTE 4 , and PGF 2 a metabolites in serum and urine showed no significant changes after the Lys-ASA BPT in patients with AERD. These discrepancies may be due to sampling time after the Lys-ASA BPT, but not to the provocation route. We collected samples immediately after positive reactions to the Lys-ASA BPT for patients with AERD, while in previous studies, samples were collected approximately 2 h after positive reactions in random urine or for 24 h [24, 25, 37, 39] . Changes in LTE 4 and PGF 2 a may be detected at least several hours after positive reactions to the Lys-ASA BPT. Further studies are warranted to determine the optimal timing for each metabolite using various sources of human samples during the Lys-ASA BPT.
In conclusion, this is the first study to demonstrate metabolite profiles for discriminating AERD from ATA, which involves arachidonic acid pathway. Our results have important clinical implication for the diagnosis of AERD, suggesting that serum levels of LTE 4 metabolite and LTE 4 /PGF 2 a metabolite ratios can be potential in vitro diagnostic biomarkers for AERD.
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